Anti-S1 or anti-receptor-binding domain antibody detectable in 17 percent of solid organ transplant recipients after first dose<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
WEDNESDAY, March 24, 2021 (HealthDay News) — Most solid organ transplant recipients do not mount an appreciable antibody response after receiving a first dose of mRNA severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, according to a research letter published online March 15 in JAMA Network Open<\/em>.<\/p>\n Brian J. Boyarsky, M.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues quantified the humoral response to the first dose of SARS-CoV-2 mRNA vaccines in solid organ transplant recipients. The proportion of patients who developed a positive antibody response was assessed among 436 transplant recipients.<\/p>\n Of the patients, 52 percent received the Pfizer-BioNTech BNT162b2 vaccine and 48 percent received the Moderna mRNA-1273 vaccine. The researchers found that antibody (anti-S1 or anti-receptor-binding domain) was detectable in 17 percent of the participants at a median of 20 days after the first dose of vaccine. The likelihood of developing an antibody response was lower among transplant recipients receiving versus not receiving anti-metabolite maintenance immunosuppression therapy (37 versus 63 percent; adjusted incidence rate ratio [IRR], 0.22). The likelihood of developing an antibody response was also lower for older transplant recipients (adjusted IRR, 0.83 per 10 years). Those who received mRNA-1273 were more likely than those receiving BNT162b2 to develop an antibody response (69 versus 31 percent; adjusted IRR, 2.15).<\/p>\n “These findings of poor anti-spike antibody responses in organ transplant recipients after the first dose of mRNA vaccines suggest that such patients may remain at higher early risk for COVID-19 despite vaccination,” the authors write.<\/p>\n Two authors disclosed financial ties to the biopharmaceutical industry.<\/p>\n